Clinical Trial Update: A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and efficacy of rilpivirine in treatment-naive HIV-1 infection patients in India has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• rilpivirine (rilpivirine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Human Immunodeficiency Virus Infections | Phase 3 | Status: TERMINATED